Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis (AD), also known as eczema. Data from the REZOLVE-AD study of ...
Two pending shareholder lawsuits with billions of dollars at stake could make it more difficult for investors to bring class actions as courts wrangle with the scope of a decade-old U.S. Supreme Court ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback